肿瘤药学2025，Vol.15Issue(1)：32-37,6.DOI:10.3969/j.issn.2095-1264.2025.01.04
外阴癌免疫治疗进展
Immunotherapy progress in vulvar cancer
摘要
Abstract
Vulvar cancer is a relatively rare gynecologic malignancy,with vulvar squamous cell carcinoma(VSCC)be-ing the most common histological subtype.VSCC can be categorized into human papillomavirus(HPV)-associated and HPV-independent types,with differences in biological behavior and prognosis.Traditional treatment for vulvar cancer in-cludes surgery,radiotherapy,and chemotherapy;however,the prognosis for patients with advanced or recurrent disease re-mains poor.Immunotherapy,particularly immune checkpoint inhibitor(ICI),has shown significant progress in the treatment of various solid tumors and has demonstrated preliminary efficacy in vulvar cancer.However,due to the rarity of vulvar can-cer,immunotherapy data are mostly derived from larger clinical studies that include vulvar cancer patients,and predictive biomarkers for efficacy,as well as optimal ICI treatment strategies,are still under investigation.Additionally,therapies such as T cell receptor-engineered T cells(TCR-T)have also shown potential benefits in vulvar cancer.This review sum-marizes the expression of common immune biomarkers,immunotherapy advances,and potential biomarkers associated with immune response in vulvar cancer,aiming to provide a reference for the immunotherapy of vulvar cancer and promote its de-velopment in clinical applications.关键词
外阴癌/免疫治疗/免疫检查点抑制剂Key words
Vulvar cancer/Immunotherapy/Immune checkpoint inhibitor分类
临床医学引用本文复制引用
陈雅萌,李宁..外阴癌免疫治疗进展[J].肿瘤药学,2025,15(1):32-37,6.基金项目
中国癌症基金会北京希望马拉松专项基金(LC2020A10). （LC2020A10）
